As­traZeneca moves ear­ly for full ap­proval with an­ti­co­ag­u­lant re­ver­sal drug An­dexxa af­ter pos­i­tive PhIV da­ta

As­traZeneca is ready to take its an­ti­co­ag­u­lant re­ver­sal agent An­dexxa in­to full ap­proval from ac­cel­er­at­ed ap­proval with the FDA, the com­pa­ny an­nounced Mon­day, based on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER